## Miscellaneous Drugs

Last Updated: March 6, 2023

<table>
<thead>
<tr>
<th>Summary Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Colchicine</strong></td>
</tr>
<tr>
<td>- The COVID-19 Treatment Guidelines Panel (the Panel) <strong>recommends against</strong> the use of colchicine for the treatment of nonhospitalized patients with COVID-19, except in a clinical trial (<strong>BIIa</strong>).</td>
</tr>
<tr>
<td>- The Panel <strong>recommends against</strong> the use of colchicine for the treatment of hospitalized patients with COVID-19 (<strong>AI</strong>).</td>
</tr>
</tbody>
</table>

**Fluvoxamine**
- There is insufficient evidence for the Panel to recommend either for or against the use of fluvoxamine for the treatment of COVID-19.

**Ivermectin**
- The Panel **recommends against** the use of ivermectin for the treatment of COVID-19 (**Alla**).

**Intravenous Immunoglobulin**
- The Panel **recommends against** the use of intravenous immunoglobulin (IVIG) for the treatment of acute COVID-19 in adults and children, except in a clinical trial (**AllI**). This recommendation should not preclude the use of IVIG when otherwise indicated for the treatment of complications that arise during the course of COVID-19.
- The Panel recommends using IVIG in combination with low to moderate dose glucocorticoids in hospitalized patients for the treatment of multisystem inflammatory syndrome in children (MIS-C) (**Allb**).
- The Panel **recommends against** the routine use of IVIG monotherapy for the treatment of MIS-C unless glucocorticoid use is contraindicated (**Allb**).

**Metformin**
- The Panel **recommends against** the use of metformin for the treatment of COVID-19 in nonhospitalized patients (**BIIa**), except in a clinical trial. And hospitalized patients (**BII), except in a clinical trial. |
- Patients with COVID-19 who are receiving metformin for an underlying condition should continue this therapy as directed by their health care provider (**AllI**). |

Each recommendation in the Guidelines receives a rating for the strength of the recommendation (A, B, or C) and a rating for the evidence that supports it (I, IIa, IIb, or III). See Guidelines Development for more information.